TrialThe New England journal of medicine2022
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Michael R Bishop et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
297 papers cite itlatest 60 shown
this paperpooled ittrialcites it